Search Thermo Fisher Scientific
- Contact Us
- Quick Order
-
Don't have an account ? Create Account
Search Thermo Fisher Scientific
Invitrogen QuantiGene Assays utilize an accurate and precise method for single or multiplexed gene expression quantitation. QuantiGene Assays incorporate branched DNA technology for accurate gene expression profiling. Branched DNA assays allow for the direct measurement of RNA transcripts by using signal amplification rather than target amplification.
Analyze 80 cytokine, chemokine, and growth factor RNA targets simultaneously for efficient immune response profiling, biomarker discovery, and validation.
A variety of formats for different research needs.
Predefined, biologically relevant, and disease-defined panels.
Custom-blended and optimized panels deliver results tailored to the panel design of your choice.
QuantiGene RNA Assays measure gene expression directly from cell and whole blood lysates or tissue homogenates without the need to purify or amplify RNA. By measuring the RNA at the sample source, the assay avoids biases and variability inherent to extraction techniques and enzymatic manipulations. In addition, this direct measurement helps overcome issues with transcript degradation typically found in samples such as FFPE. Direct measurement is possible because target RNAs are captured through probe hybridization and quantified through branched DNA technology that amplifies the signal. The signal is read using a Luminex instrument for multiplex assays or a luminometer for single targets.
QuantiGene assays demonstrate high data concordance between multiple gene expression platforms (qPCR, microarrays), which allow the ability to switch technologies without having to repeat experiments.
QuantiGene Plex and SinglePlex assays utilize branched DNA (bDNA) technology. bDNA technology utilizes sequential nucleic acid hybridization for a unique approach to RNA and DNA quantification by amplifying a reporter signal rather than the template. This measures the transcripts at physiological levels.
First, cells are lysed or tissue samples are homogenized to release the target RNA or DNA. Second, an oligonucleotide probe set is incubated with the target RNA or DNA. During this incubation, the probes cooperatively hybridize to the target. Third, signal amplification is performed via sequential hybridization of the bDNA pre-amplifier, amplifier, and labeled probe molecules to the target. Addition of a chemiluminescent substrate (singleplex assays) or fluorescent reporter (multiplex asssays) generates a signal directly proportional to the amount of target RNA or DNA present in the sample.
A pair of target-specific probe sets (Target Probe), approximately 20 nucleotides in length, hybridizes to contiguous sequences on the target RNA (or DNA). Signal amplification is achieved through successive hybridization of short oligonucleotide sequences to build the bDNA structure (bDNA "tree"), formed by Preamplifiers, Amplifiers, and Labeled Probe, resulting in excellent specificity, low background, and high signal-to-noise ratio.
The QuantiGene assay offers an alternative to qPCR with the ability to multiplex up to 80 gene targets directly from cell lysates, whole blood lysates, or tissue homogenates in a convenient plate-based format. While qPCR is considered the gold standard and traditional technology for gene expression analysis to study gene regulation, gene variation, and differential gene expression, a number of steps are required including the isolation of RNA and reverse transcription before performing the qPCR assay. Innovations like Thermo Fisher Scientific’s Cells-to-CT Kits enable measurement of relative gene expression by real-time RT-PCR directly from cultured cells, but direct-from-sample measurement across many different sample types remains a challenge. QuantiGene Assays provide a useful alternative to directly measure RNA expression across multiple different sample types and require minimal method development and optimization.
QuantiGene Plex and SinglePlex assays utilize branched DNA (bDNA) technology. bDNA technology utilizes sequential nucleic acid hybridization for a unique approach to RNA and DNA quantification by amplifying a reporter signal rather than the template. This measures the transcripts at physiological levels.
First, cells are lysed or tissue samples are homogenized to release the target RNA or DNA. Second, an oligonucleotide probe set is incubated with the target RNA or DNA. During this incubation, the probes cooperatively hybridize to the target. Third, signal amplification is performed via sequential hybridization of the bDNA pre-amplifier, amplifier, and labeled probe molecules to the target. Addition of a chemiluminescent substrate (singleplex assays) or fluorescent reporter (multiplex asssays) generates a signal directly proportional to the amount of target RNA or DNA present in the sample.
A pair of target-specific probe sets (Target Probe), approximately 20 nucleotides in length, hybridizes to contiguous sequences on the target RNA (or DNA). Signal amplification is achieved through successive hybridization of short oligonucleotide sequences to build the bDNA structure (bDNA "tree"), formed by Preamplifiers, Amplifiers, and Labeled Probe, resulting in excellent specificity, low background, and high signal-to-noise ratio.
The QuantiGene assay offers an alternative to qPCR with the ability to multiplex up to 80 gene targets directly from cell lysates, whole blood lysates, or tissue homogenates in a convenient plate-based format. While qPCR is considered the gold standard and traditional technology for gene expression analysis to study gene regulation, gene variation, and differential gene expression, a number of steps are required including the isolation of RNA and reverse transcription before performing the qPCR assay. Innovations like Thermo Fisher Scientific’s Cells-to-CT Kits enable measurement of relative gene expression by real-time RT-PCR directly from cultured cells, but direct-from-sample measurement across many different sample types remains a challenge. QuantiGene Assays provide a useful alternative to directly measure RNA expression across multiple different sample types and require minimal method development and optimization.
Discover key I‑O research approaches, including checkpoint inhibitor therapy research, CAR T cell therapy research, and cancer vaccine therapy research.
Explore Luminex systems: MAGPIX, Luminex 200, and FLEXMAP3D.
Multiplex immunoassays using the Luminex platform.
Microarray platform for fast, detailed transcriptome-wide expression profiling.
TaqMan Gene Expression Assays, master mixes and instrumentation.
For Research Use Only. Not for use in diagnostic procedures.